Results 31 to 40 of about 7,937 (163)

Estimating the “First in human” dose – a revisit with particular emphases in oncology drugs

open access: yesADMET and DMPK, 2013
The initial dose selection is one of the important steps for any investigative new drug (IND) entering the first clinical study in human. In this mini review, we will discuss the no observed adverse effect level (NOAEL) and the minimum anticipated ...
Kin Tam
doaj   +1 more source

Safety evaluation of a novel variant of consensus bacterial phytase

open access: yesToxicology Reports, 2020
A 90-day subchronic oral toxicity study was conducted to evaluate the safety of a consensus bacterial phytase variant 6-phytase (PhyG) for use as an animal feed additive.
Gregory S. Ladics   +6 more
doaj   +1 more source

Reevaluation of the acute toxicity of palytoxin in mice: Determination of lethal dose 50 (LD50) and No-observed-adverse-effect level (NOAEL)

open access: yesToxicon, 2020
Palytoxin is an emergent toxin in Europe and one of the most toxic substances know to date. The toxin disrupts the physiological functioning of the Na+/K+-ATPase converting the enzyme in a permeant cation channel. Human intoxications by PLTX after consumption of contaminated fishery products are a serious health issue and can be fatal.
Andrea Boente-Juncal   +5 more
openaire   +3 more sources

Towards establishing no observed adverse effect levels (NOAEL) for different sources of dietary phosphorus in feline adult diets: results from a 7-month feeding study [PDF]

open access: yesBritish Journal of Nutrition, 2020
Abstract High dietary phosphorus (P), particularly soluble salts, may contribute to chronic kidney disease development in cats. The aim of the present study was to assess the safety of P supplied at 1 g/1000 kcal (4184kJ) from a highly soluble P salt in P-rich dry format feline diets.
Jennifer C, Coltherd   +12 more
openaire   +2 more sources

Risk Assessment of Isoeugenol in Food Based on Benchmark Dose—Response Modeling

open access: yesToxics, 2023
Isoeugenol has recently been evaluated as possibly carcinogenic (Group 2B) by the WHO International Agency for Research on Cancer (IARC). In light of this evaluation, an updated risk assessment of this common food constituent was conducted using the ...
Thomas Quentin   +2 more
doaj   +1 more source

The NOAEL Metformin Dose Is Ineffective against Metabolic Disruption Induced by Chronic Cadmium Exposure in Wistar Rats

open access: yesToxics, 2018
Previous studies have proposed that cadmium (Cd) is a metabolic disruptor, which is associated with insulin resistance, metabolic syndrome, and diabetes. This metal is not considered by international agencies for the study of metabolic diseases.
Victor Enrique Sarmiento-Ortega   +7 more
doaj   +1 more source

A 14-day repeated-dose oral toxicological evaluation of an isothiocyanate-enriched hydro-alcoholic extract from Moringa oleifera Lam. seeds in rats

open access: yesToxicology Reports, 2018
A 14-d short-term oral toxicity study in rats evaluated the safety of moringa isothiocyanate-1 (MIC-1)-enriched hydro-alcoholic moringa seeds extract (MSE).
Youjin Kim   +4 more
doaj   +1 more source

The Effect of Zearalenone on the Cytokine Environment, Oxidoreductive Balance and Metabolism in Porcine Ileal Peyer’s Patches

open access: yesToxins, 2020
The aim of the present study was to determine the effect of zearalenone (ZEN), administered per os to gilts at doses equivalent to 50%, 100%, and 150% of no-observed-adverse-effect level (NOAEL) values for 14, 28, and 42 days during weaning, on changes ...
Kazimierz Obremski   +5 more
doaj   +1 more source

Determining a NOAEL for the consortium linking academic and regulatory insights on BPA toxicity (CLARITY-BPA) core study

open access: yesFrontiers in Toxicology
The CLARITY-BPA Core Study is the most comprehensive animal study of oral bisphenol A (BPA) exposure to date. Rats were exposed daily, in utero until postnatal day 21 or for the animals’ lifetime.
Melissa Badding   +2 more
doaj   +1 more source

Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV‐3 in a Controlled Human Infection Model

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM).
Nele Goeyvaerts   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy